Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron and Fluorastrol

Human kinesin Eg5, which plays an essential role in mitosis by establishing the bipolar spindle, has proven to be an interesting drug target for the development of cancer chemotherapeutics. Here, we report the crystal structures of the Eg5 motor domain complexed with enastron, dimethylenastron, and fluorastrol. By comparing these structures to that of monastrol and mon-97, we identified the main reasons for increased potency of these new inhibitors, namely the better fit of the ligand to the allosteric binding site and the addition of fluorine atoms. We also noticed preferential binding of the S-enantiomer of enastron and dimethylenastron to Eg5, while the R-enantiomer of fluorastrol binds preferentially to Eg5. In addition, we performed a multidrug resistance (MDR) study in cell lines overexpressing P-glycoprotein (Pgp). We showed that one of these inhibitors may have the potential to overcome susceptibility to this efflux pump and hence overcome common resistance associated with tubulin-targeting drugs

sp3 C–H Bond Functionalization with Ruthenium Catalysts

International audienceThe selective formation of carbon–carbon bond by functionalization of an sp3C–H bond is still a challenge in organic synthesis. There are already examples involving transition metal catalysis. In this chapter we review the use of ruthenium(0) and ruthenium(II) catalysts for the formation of carbon–carbon bonds based on creation of reactive sites by sp3C–H bond activation. We show that in most cases, regioselective sp3C–H bond activation is induced either from functional substrates bearing a directing group, which strongly coordinates the metal centre, or by selective C–H bond activation at the α-carbon of a heteroatom accompanied by hydrogen transfer processes and transient creation of reactive functional group